Alain Leizorovicz

Samuel Z. Goldhaber, M.D ., Alain Leizorovicz, M.D., Ajay K. Kakkar, M.D., Ph.D., Sylvia K. Haas, M.D., Ph.D., Geno Merli, M.D., Robert M. Knabb, Ph.D., and Jeffrey I. Weitz, M.D. For the ADOPT Trial Investigators: Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients Venous thromboembolism is normally a common and potentially fatal complication in hospitalized surgical patients and acutely ill medical patients.1 The advantages of providing pharmacologic thromboprophylaxis over the complete course of the hospital stay have been validated, with efficacy and safety shown in both populations.2-5 Among high-risk surgical individuals, such as those undergoing total hip alternative, extended thromboprophylaxis in the time following hospital discharge has reduced the rate of both symptomatic and asymptomatic venous thromboembolism.6 Based on these findings, current practice guidelines recommend extended thromboprophylaxis in such patients.7 One study 8 evaluated the potential benefit of extending pharmacologic prophylaxis with enoxaparin beyond the time of hospitalization in acutely ill medical individuals.

Among the Kirby Lester Robotics Consumer Research's findings: 92 percent – – the Kirby Lester robot significantly reduced time and tension during Pharmacist Check 85 percent – – the Kirby Lester robot preserved 5-10 hours per week in technician labor by itself 78 percent – – the Kirby Lester robot allowed the pharmacy to increase or expand business 74 percent – – the Kirby Lester robot allowed the pharmacy to increase prescription quantity without adding additional personnel 85 percent – – pharmacies processing only 150-200 prescriptions per day would reach positive ROI with a Kirby Lester robot Kirby Lester invented the tablet counter in 1971.